| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 573 | 710 | 650 | $90 | $274.1K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 378 | 690 | 650 | $90 | $235.4K |
| 99203 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the provider… | 102 | 170 | 120 | $70 | $35.7K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 3 | 10 | 70 | $20 | $30.1K |
| 90471 | In this procedure, the provider administers a live attenuated vaccine using a percutaneous, intradermal, subcutaneous, or intramuscular route. | 96 | 230 | 140 | $20 | $16.1K |
| 99211 | An established patient presents for an office or other outpatient visit that may not require the presence of a physician or other qualified healthcare professional. | 1 | 90 | 180 | $10 | $14.5K |
| 87426 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient blood specimen for antigens of severe acute respiratory syndrome coronavirus such as SARS–CoV–2,… | 5 | 40 | 170 | $20 | $13K |
| 3008F | No Summary found for this code | 44 | 90 | 660 | $1 | $1.9K |
| 90674 | This code represents a flu vaccine product that protects against four strains of influenza. It is derived from cell cultures, contains no preservatives or antibiotics, and is administered as a 0.5 mL… | 56 | 60 | 50 | $20 | $1.3K |
| 1036F | N/A | 32 | 120 | 160 | $1 | $110 |